90-Day Analysis Shows Moderna's Omicron BA.1-Targeting Bivalent Vaccine, mRNA-1273.214, Demonstrates Superior Antibody Response as Fourth Booster Compared to Spikevax Prototype Booster
yahoo.com
economics
2022-10-19 12:00:00

Data indicate durable immune response from bivalent booster after three months of follow-up

mRNA-1273.214 also demonstrated potent response to Omicron BA.2.75

CAMBRIDGE, MA / ACCESSWIRE / October 19, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214. Ninety days after administration as a fourth booster dose in previously vaccinated and boosted participants, a 50 Âµg booster dose of mRNA-1273.
